Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

• C2-deficient SLE, factor B and, 427
• C4, factor B, and C2 deficiency in SLE, 427
• C5 in collagen-induced arthritis in mice, 256
• Calcium channel blockers in SSc renal crisis, 1613
• Calcium and prostaglandin E2 release in RA, 246
• cAMP synthesis in OA, 891
• Camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 730
• Canine models
  • intraarticular hyaluronan in OA, 976
  • NO synthase inhibition and reduction of OA progression, 1275
• Cannabinoids, antiinflammatory activity of, 163
• Carpal tunnel syndrome
  • median nerve compression in, 720
  • pseudogout in, 182
• Cartilage
  • antisense inhibition of CD44 and chondrolysis of, 1411
  • link protein stimulation of proteoglycan biosynthesis in, 157
  • MRI of normal and OA, 963
  • repair and transplantation of, 1331
  • type VI collagen in normal and OA, 986
  • type X collagen in OA, 1287
• Cartilage destruction
  • and chondrocyte apoptosis, 1632
  • inhibition of proteoglycans in, 274
  • and joint disuse, 2068
  • oncostatin M in, 1760
  • stromelysin in, 110
• Cartilage oligomeric matrix protein (COMP)
  • in chronic erosive arthritis in rats, 544
  • degradation by matrix metalloproteinases, 2143
  • in synovial cells and articular chondrocytes, 997
• Cartilage-derived morphogenetic proteins, in articular cartilage and matrix replacement in vitro, 263
• Caspase and apoptosis, 1
• Cathepsin and matrix metalloproteinase expression in RA and OA, 1378
• C57Bl/6-lpr/lpr mice and murine cytomegalovirus, SS-like disease in, 2175
• CD4
  • in arthritis associated with HIV and hepatitis C virus, 740
  • in RA, 1669, 1906
  • RA synovial antigen, recognition by, 92
  • in reactive arthritis, 315
  • in rheumatoid synovitis, cell subsets in, 2110
  • tissue inhibitor of metalloproteinases 1 in synovial tissue and, 1748
• CD8
  • in RA, 498
  • RA synovial antigen, recognition by, 92
  • in reactive arthritis, 315
  • in SLE, 823
  • tissue inhibitor of metalloproteinases 1 in synovial tissue and, 1748
• CD20 in leukemic arthritis, 1695
• CD28 in rheumatoid synovitis, 2108
• CD40L and CD4 subsets in rheumatoid synovitis, 2108
• CD44, antisense inhibition of, and cartilage chondrolysis, 1411
• CD49d γ/δ T cells, in SSc, 327
• CD54 on human articular chondrocytes, 1296
• CD68 in RA, 306
• CD88 in RA, 233
• CD95
  • apoptosis and, 205, 215
  • signaling mutant, molecular characterization of, 1047
• CD106 on human articular chondrocytes, 1296
• CD166 expression on monocytes and in RA synovium, 2221
• CDR3, in human T cell leukemia virus type I, 101
• CD45RO in RA, 92
• Celecoxib (SC-58635), safety and efficacy of, 1591
• Cellular immunity, human cytomegalovirus associated with, 10
• Cerebrovascular accident and visual loss in giant cell (temporal) arteritis, 1497
• Chemokines
  • CCR5 receptor in RA, 1135
  • interleukin-8 receptor binding, in gout, 900
  • in rheumatoid synovitis, 1365
• Children. See also entries beginning with 'Juvenile'
  • anti-ribosomal P autoantibodies in healthy, 33
  • Henoch-Schonlein purpura in, 1518
  • MTX in childhood rheumatic diseases, 381
• Chlamydia pneumoniae in rheumatic diseases, 845, 1894
• Chlamydia trachomatis
  • in reactive arthritis, 1894
  • in rheumatic diseases, 845
• Chlorambucil associated with the development of myelodysplastic syndromes, 1493
• 2-chloro-2`-deoxyadenosine (2-CdA) in the treatment of SLE-associated glomerulonephritis, 335, 1704
• Chondrocytes
  • apoptosis in OA, 285, 1266, 1632
  • cartilage oligomeric matrix protein in, 997
  • formation of, 1645
  • interferon-γ and tumor necrosis factor α effects on protein in human, 274
  • leukotriene A4 hydrolase and leukotriene C4 synthetase in human, 1645
  • paclitaxel effect on, 869
  • parathyroid hormone-related protein and transforming growth factor in, 2152
  • type VI collagen in normal and OA cartilage, 986
  • vascular cell adhesion molecules on human articular, 1296
• Chronic arthritis
  • cartilage oligomeric matrix protein in rats with, 544
  • interleukin-1 receptors in, 1083
  • juvenile, sulfasalazine in the treatment of, 808
• Chronic pain syndrome and neck injury, 758
• Churg-Strauss syndrome (CSS)
  • serology in, 445
  • treatment of, 2100
• Ciprofloxacin in antiphospholipid syndrome, 224
• Circadian studies, dysautonomia in fibromyalgia, 1966
• Codeine and oxycodone for pain in rheumatic diseases, 1603
• Cognitive function in SLE, 41
• Colchicine clearance by high-flux polysulfone dialyzers, 749
• Collagen crosslinks in fibromyalgia, 948
• Collagen type I
  • activated T cell inhibition of the production of, 2039
  • α1(I) procollagen gene expression in SSc, 2048
  • vitamin D receptor, COL1A1, and COL2A1 gene polymorphisms and hip OA in postmenopausal women, 1946
• Collagen type II
  • IL-6 and, in collagen-induced arthritis, 2117
  • new non-MHC and, in collagen-induced arthritis, 2122
  • oral, in the treatment of RA, 191, 291
  • versus proteoglycan-induced polyarteritis, 1007
  • vitamin D receptor, COL1A1, and COL2A1 gene polymorphisms and hip OA in postmenopausal women, 1946
• Collagen type VI in normal and OA cartilage, 986
• Collagen type X
  • in articular cartilage, 1287
  • nonisomerized and β-isomerized breakdown products in Paget's disease, 354
  • procollagen gene expression in SSc, 2048
  • procollagen gene expression in tight skin 2 mice, 2132
• Collagenase 1 (MMP-1)
  • expression in guinea pig OA, 877
  • inhibition by interleukin-4 in synovial fibroblasts, 1398
  • paclitaxel inhibition of expression of, 869
• Collagenase 3 (MMP-3), expression in guinea pig OA, 877
• Collagenase inhibitor Ro 32-3555 in murine OA, 1639
• Collagen-induced arthritis (CIA)
  • anti-interleukin-6 suppression of, 2117
  • cyclosporine and anti-tumor necrosis factor α in, 1806
  • genetic control of, 256
  • new non-MHC genetic loci and, 2122
  • in nonhuman primates, 507
  • susceptibility and cartilage destruction in stromelysin-deficient mice, 110
  • susceptibility and interleukin-1 receptor antagonist, 1798
• Coronary restenosis, human cytomegalovirus and vasculopathy of, 10
• Corticosteroids
  • actions of, in rheumatic diseases, 761
  • -induced osteoporosis in SLE, 171
  • in JRA, 1210
  • in RA, 564, 1203, 1709, 1710
  • in SSc renal crisis, 1613
• Cost-effectiveness, of misoprostol, 16
• CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias)
  • in the hand, 373
  • in RA/limited cutaneous SS, 1938
• Cryoglobulinemia and arthralgia in HIV and hepatitis C virus, 740
• C-telopeptide breakdown products (CTX), type I collagen, in Paget's disease, 354
• CTLA-4, in SLE susceptibility, 596
• CXCR-2, in gout, 900
• Cyclooxygenase 1 (COX-1), in human synovial tissue, 122
• Cyclooxygenase 2 (COX-2)
  • DMH-11C inhibition of, 163
  • effect of Tripterygium wilfordii Hook F on activity of, 130
  • in human synovial tissue, 122
  • safety and efficacy of inhibitor SC-58635, 1591
• Cyclophosphamide (CYC)
  • associated with development of myelodysplastic syndromes, 1493
  • intravenous pulse, for interstitial lung disease, 1215
  • intravenous pulse versus oral, in ANCA-associated vasculitis, 1835
  • in plasmapheresis-treated SLE, 414
  • pulse versus oral, in Wegener's granulomatosis, 1705, 1706
  • -treated SLE, ovarian failure in, 831
• Cyclosporine
  • -associated bone pain, 565
  • in collagen-induced arthritis, 1806
  • in RA, MTX combination therapy and, 1703
  • in RA, risks of treatment, 1930
  • and recurrent lupus nephritis after renal transplantation, 678
• Cytokines. See also Th1 cytokines; Th2 cytokines
• inhibition of proteoglycans in cartilage destruction, 274
• in leukemic arthritis, 1695
• modulation of vascular endothelial growth factor in RA, 1258
• and MTX in RA, 48
• in OA chondrocyte inflammation, 2165
• production in rheumatoid nodules, 1783
• single-cell analysis of, in RA, 1669
• Cytomegalovirus
  • human, and vasculopathies of autoimmune diseases, 10
  • murine, SS-like disease in C57Bl/6-lpr/lpr mice, 2175
• Cytotoxic treatments for refractory myositis, 392
• Cytotoxicity of T cells, in extraarticular RA, 2108